




# REVISTA DE GASTROENTEROLOGÍA DE MÉXICO

[www.elsevier.es/rgmx](http://www.elsevier.es/rgmx)



## ORIGINAL ARTICLE

# Approach, attitudes, and knowledge of general practitioners in relation to *Helicobacter pylori* is inadequate. There is much room for improvement! ☆



A.D. Cano-Contreras, O. Rascón, M. Amieva-Balmori, S. Ríos-Gálvez, Y.J. Maza, A. Meixueiro-Daza, F. Roesch-Dietlen, J.M. Remes-Troche \*

Laboratorio de Fisiología Digestiva y Motilidad Gastrointestinal, Instituto de Investigaciones Médico Biológicas, Universidad Veracruzana, Veracruz, Mexico

Received 30 March 2016; accepted 22 February 2017

Available online 6 September 2017

### KEYWORDS

*Helicobacter pylori*;  
Knowledge;  
Eradication;  
Mexico

### Abstract

**Background:** *Helicobacter pylori* (*Hp*) infection is one of the most common infections in humans. Due to its worldwide prevalence, a series of guidelines and recommendations has been developed for the appropriate screening, diagnosis, and management of patients with *Hp* infection. **Aim:** To evaluate the approach, attitudes, and knowledge of a group of Mexican general practitioners in relation to *Hp*.

**Materials and methods:** A cross-sectional study was conducted that evaluated the knowledge of *Hp* diagnosis and treatment through the application of a questionnaire.

**Results:** From the total of 430 questionnaires delivered, information was obtained from 411 (95% response rate). The most frequent indications for eradication treatment were peptic ulcer (48.4%), gastroesophageal reflux disease (41.8%), and dyspepsia (39.2%). Thirty-one percent of the physicians surveyed used more than one test to look for *Hp*, and serology was the most commonly employed method. The most widely used antibiotic regimen was clarithromycin plus amoxicillin (63.8%), followed by metronidazole plus tetracycline (16%). Ninety-two percent of the physicians confirmed eradication through endoscopy for the histologic analysis and only 23% utilized the breath test.

☆ Please cite this article as: Cano-Contreras AD, Rascón O, Amieva-Balmori M, Ríos-Gálvez S, Maza YJ, Meixueiro-Daza A, et al. El abordaje, las actitudes y el conocimiento acerca de *Helicobacter pylori* en médicos generales es deficiente ¡Hay mucho que mejorar! Revista de Gastroenterología de México. 2018;83:16–24.

\* Corresponding author. Laboratorio de Fisiología Digestiva y Motilidad Gastrointestinal, Instituto de Investigaciones Médico Biológicas, Iturbide SN, Colonia Flores Magón, C.P. 91400, Veracruz, Mexico.

E-mail addresses: [jose.remes.troche@gmail.com](mailto:jose.remes.troche@gmail.com), [joremes@uv.mx](mailto:joremes@uv.mx) (J.M. Remes-Troche).

**PALABRAS CLAVE**

*Helicobacter pylori*;  
Conocimiento;  
Erradicación;  
México

**Conclusions:** Our results show the lack of knowledge about the established diagnostic and treatment recommendations for *Hp* infection. The implementation of workshops, courses, and conferences, or the formulation of practical guidelines should be directed at primary care physicians to strengthen the practice of medicine based on scientific evidence.

© 2017 Asociación Mexicana de Gastroenterología. Published by Masson Doyma México S.A. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## El abordaje, las actitudes y el conocimiento acerca de *Helicobacter pylori* en médicos generales es deficiente ¡Hay mucho que mejorar!

**Resumen**

**Antecedentes:** La infección por *Helicobacter pylori* (*Hp*) es una de las más comunes en el humano. Debido a su alta prevalencia a nivel mundial se ha desarrollado una serie de guías y recomendaciones para el apropiado escrutinio, diagnóstico y manejo de los pacientes con *Hp*. **Objetivo:** Evaluar el abordaje, las actitudes y el conocimiento acerca de *Hp* en un grupo de médicos generales en nuestro país.

**Materiales y métodos:** Estudio transversal en el cual se evaluaron, mediante la aplicación de un cuestionario, los conocimientos acerca del diagnóstico y tratamiento de *Hp*.

**Resultados:** De un total de 430 encuestas entregadas, se obtuvo información proveniente de 411 (tasa de respuesta del 95%). Las indicaciones más frecuentes de tratamiento de erradicación fueron la úlcera péptica (48.4%), la enfermedad por reflujo gastroesofágico (41.8%) y la dispepsia (39.2%). El 31% de los médicos utilizan más de una prueba para la búsqueda del *Hp*, de las que la serológica es la más utilizada. El esquema de antibióticos más utilizado es claritromicina más amoxicilina (63.8%), seguido de metronidazol más tetraciclina (16%). El 92% de los médicos corroboran la erradicación mediante una endoscopia para el análisis histológico y la prueba de aliento solo se utiliza en el 23%.

**Conclusiones:** Nuestros resultados muestran la carencia de conocimientos sobre las recomendaciones de diagnóstico y tratamiento establecidas en la infección por *Hp*. La implementación de talleres, cursos, conferencias o la elaboración de guías prácticas deben dirigirse a los médicos de primer contacto con la finalidad de fortalecer la práctica médica basada en la evidencia científica.

© 2017 Asociación Mexicana de Gastroenterología. Publicado por Masson Doyma México S.A. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

**Introduction**

*Helicobacter pylori* (*H. pylori*) infection continues to be one of the most common infections in humans.<sup>1</sup> Up to half of the world population can have gastric colonization of this bacterium (Gram-negative, microaerophilic). Its most virulent strains (CagA +) have been related to different gastroduodenal pathologies, such as chronic gastritis, peptic ulcer, type B gastric lymphoma (MALT), and the possibility of developing adenocarcinoma through chronic alterations, such as atrophy and metaplasia.<sup>2</sup>

The prevalence of *H. pylori* varies, depending on factors such as socioeconomic status, hygienic conditions, lack of potable water, and overcrowding. Therefore, its frequency is greater in developing countries (70 to 90%), compared with developed countries (30 to 50%), and the infection is acquired in early childhood.<sup>3</sup> A report from the World

Gastroenterology Organization in 2010<sup>4</sup> reported the worldwide prevalence of *H. pylori* infection, and it included Central American and South American countries. In Mexico, prevalence in children between the ages of 5 and 9 years was 43%, and it was 70-90% in adults. In Guatemala, prevalence in children from 5 to 10 years was 51%, and 65% in adults.<sup>4</sup> Prevalence in Bolivia, Brazil, and Chile varied from 30 to 54% in children and adolescents, and from 70 to 90% in adults.<sup>4</sup>

In Mexico, a national survey on an open population (n = 11,605) that used serum antibody determination as the screening method found an overall frequency of 66%.<sup>5</sup> Seropositivity rose in direct relation to age, with figures higher than 80% in subjects over 30 years of age.<sup>5</sup>

Due to the high prevalence of *H. pylori* worldwide, a series of guidelines and recommendations for the appropriate screening, diagnosis, and management of patients with

*H. pylori* infection have been developed within the last few years. The most recent Maastricht V Consensus<sup>6</sup> reaffirms previous recommendations that have been sustained over time, such as eradicating the bacterium in patients with *H. pylori* and peptic ulcer, or eradication therapy as first-line treatment for low-grade gastric lymphomas (MALTomas).<sup>6</sup> With respect to diagnosis, the main noninvasive tests that can be used for the "search and treat" strategy are the labelled urease breath test or the monoclonal antibody-based stool antigen test (Level of evidence: 2a; Grade of recommendation: B).<sup>6</sup>

In Mexico, a consensus published in 2007 (Third Mexican Consensus on *Helicobacter pylori*) established the guidelines for making decisions concerning this situation in our country.<sup>7</sup> Those guidelines and recommendations consider specific situations, such as the high prevalence of *H. pylori*, the high frequency of infection in certain groups, and the lack of resources at some healthcare facilities for conducting special tests, as well as the high resistance to antibiotics.<sup>7</sup>

An elevated prevalence of gastrointestinal diseases or symptoms (for example, dyspeptic symptoms) in populations where *H. pylori* infection is high, implies that a large number of subjects receive primary health care. Therefore, it is essential that primary care physicians have the appropriate knowledge for making adequate decisions and preventing incorrect practices that result in elevated costs and absolutely no health benefits for the population. Even though there are initiatives in other countries for educating primary care physicians with respect to the diagnosis and adequate management of this infection, the results of various surveys carried out in developing countries reveal confusion and discrepancies regarding the pathogenesis, diagnosis, and treatment of *H. pylori*.<sup>8-11</sup> A Peruvian study showed that up to 60% of primary care physicians and 69% of internists used inappropriate regimens for eradicating *H. pylori* and that only 8% knew this infection was associated with MALT lymphomas.<sup>12</sup>

Despite the high prevalence of *H. pylori* in Mexico, there are no previous studies conducted on primary care physicians with respect to their knowledge and practice in relation to *H. pylori* infection. The aim of the present study was to evaluate the approach to, attitudes about, and knowledge of *H. pylori* infection in a group of general practitioners in Mexico.

## Materials and methods

A prolective and cross-sectional study was conducted through a questionnaire (11 questions, Annex 1) designed to evaluate the knowledge of the diagnosis and treatment of *H. pylori* on the part of general practitioners from the 32 States of the Mexican Republic that attended a training course (2 days, 8 h each day) on gastrointestinal diseases, in groups of 30 to 40, at the *Instituto de Investigaciones Médico Biológicas* of the *Universidad Veracruzana* within the time frame of May 2013 and February 2015. All the questionnaires were answered anonymously, in blinded form, and voluntarily, before the commencement of the academic activities. Convenience sampling (non-probabilistic) was employed for the study. The Research and Ethics Committee of the *Insti-*

**Table 1** Symptoms that were considered caused by *Helicobacter pylori* infection.

Symptom	Frequency (n,%)	95% CI
Halitosis	207 (50.4)	45-55
Cough	104 (25.3)	21-29
Pharyngitis	110 (26.8)	22-31
Asthma	41 (10)	7-13
Dental erosions	63 (15.3)	12-19
Burping	187 (45.5)	40-50
Heartburn	295 (71.8)	67-75
Regurgitation	236 (57.4)	52.5-62
Chest pain	153 (37.2)	32.6-42
Satiety	129 (31.4)	27-36
Epigastric pain	316 (76.9)	72.5-80
Abdominal bloating	199 (48.4)	43-53
Inflammation	118 (28.7)	24.5-33
Constipation	47 (11.4)	8.7-14
Diarrhea	45 (10.9)	8.2-14

*tuto de Investigaciones Médico Biológicas* approved the work.


Descriptive statistics were carried out and the frequencies (95% confidence intervals) of the answers obtained for each question were calculated. The chi-square test and Student's t test, as appropriate, were used for the univariate analysis, and statistical significance was set at a p under 0.05. The multivariate analysis employed the ANOVA test and multinomial logistic regression. The statistical analysis was performed using the SPSS version 16 program (Chicago, Illinois, USA).

## Results


Of the total of 430 surveys given out, information was obtained from 411 (95% response rate). The total of 411 subjects evaluated consisted of 217 men (53%) and 194 women (47%), with a mean age of  $50.9 \pm 10.4$  years (range: 23-78 years). The physicians had been practicing general medicine for a mean 5.7 years (range: 2-23 years) and saw a mean 14 patients (range: 8-22) per day. Figure 1 shows the percentage of physicians that came from the eight different geographic zones of Mexico.

Of the total of the subjects evaluated, 339 (82.5%; CI, 78-85%) thought that *H. pylori* infection could cause gastrointestinal esophageal reflux disease (GERD) and 185 (45%; CI, 40%-49%) considered it the main cause of dyspepsia. The physicians thought that *H. pylori* caused GERD more frequently than dyspepsia (OR: 5.75; 95% CI: 4.17-7.92; p = 0.005). Table 1 shows a list of symptoms and the frequency with which the study group regarded them as the consequence of *H. pylori* infection. Only 21% (n = 88) of the physicians surveyed stated having knowledge of the estimated prevalence of *H. pylori* in Mexico and the mean of that estimated prevalence was 55.14% (range: 15-92%).

Figure 2 shows the most frequent indications for which the physicians prescribed *H. pylori* eradication treatment, based on accepted recommendations according to the Maas-



**Figure 1** Percentage of physicians evaluated by geographic zone.



**Figure 2** Most frequent indications for *Helicobacter pylori* eradication.

tricht Consensus, as well as other recommendations with no scientific evidence.

Figure 3 shows that the use of a single test ( $n = 127$ , 31%) was the most common for diagnosing *H. pylori* infection. Of those 127 physicians, 89% ( $n = 113$ ) used 2 tests for making the diagnosis. The most frequent combination was serology + histology (77%), serology + breath test (18%), and histology + breath test (5%). Eleven percent ( $n = 14$ ) stated that they used 3 tests, and the most common combination was serology + histology + breath test. When just one test was used, serology was the most common (23.4%). It was striking that the detection of fecal antigens in stool samples was hardly used (0.5%).

Table 2 shows the different antibiotic regimens used by the 397 subjects that indicated *H. pylori* eradication. The most widely used proton pump inhibitor (PPI) for the eradication scheme was omeprazole (46%), followed by pantoprazole (23%), and esomeprazole (15%) (Table 3). Figure 4

**Table 2** Antimicrobial eradication regimens prescribed with greatest frequency.

Antibiotics	n (%)
Amoxicillin + clarithromycin	260 (63.8)
Metronidazole + tetracycline + bismuth	68 (16)
Amoxicillin + clarithromycin + metronidazole	26 (7)
Ampicillin + clarithromycin	6 (1.5)
Amoxicillin + azithromycin	6 (1.5)
Ciprofloxacin + clarithromycin	5 (1.2)
Clindamycin + metronidazole	7 (3)
Erythromycin + metronidazole	4 (1)
Levofloxacin + clarithromycin	8 (2.4)
Trimethoprim/sulfamethoxazole	3 (0.9)
Amoxicillin + clavulanic acid	3 (1.7)




Figure 3 *Helicobacter pylori* diagnostic studies used with the greatest frequency.

shows the duration of the prescribed treatment, and the most frequent (75%) was administration of the regimen employed for 14 days, followed by the uncommon recommendation of one-month regimens (8%).

Ninety-two percent (n = 365) of the physicians corroborated the eradication of the bacterium after *H. pylori* eradication treatment and Figure 5 shows the methods utilized for its confirmation. It is surprising that the most common method for confirming eradication was a new endoscopy for histologic analysis and that the breath test was only used by 23% of the physicians. No statistically significant differences were found upon analyzing results according to the region the general practitioners were from, age, sex, or time practicing medicine (p > 0.05)

### Discussion

*H. pylori* infection is frequent worldwide and the greatest number of cases are reported in developing countries.




Figure 4 Indicated treatment duration in *Helicobacter pylori* eradication.




Figure 5 Diagnostic tests used with the greatest frequency to corroborate *Helicobacter pylori* eradication.

Table 3 Proton pump inhibitors used in the *Helicobacter pylori* eradication regimens.

Proton pump inhibitors	n (%)
Omeprazole	188 (6)
Pantoprazole	95 (23)
Lansoprazole	60 (15)
Esomeprazole	48 (12)
Dexlansoprazole	11 (2)
Omeprazole + HCO <sub>3</sub>	3 (1)

In Mexico, primary health care is handled by general practitioners or family physicians that have the first contact with patients. Thus, we paid special attention to this broad group, discovering important deficiencies in their knowledge, especially concerning the recommendations for the diagnosis and treatment of *H. pylori* infection. That information revealed an area of special interest for carrying out educational medical activities to improve primary health care.

The Maastricht V Consensus made recommendations about diagnostic strategies and treatment indications for *H. pylori* infection, considering it adequate to carry out intentional search and treatment in patients with uninvestigated dyspepsia, when there is high prevalence in the population (>20%). This is still a subject of debate in the Mexican environment, in which rates above 70% in the adult population have been reported, without taking patients with



alarm symptoms into account (Level of evidence: 1a; Grade of recommendation: A). In a study involving 509 primary care physicians, Ahmed et al.<sup>13</sup> reported the presence of dyspepsia symptoms (67%) as the main indication for performing a diagnostic test, followed by GERD, gastric or duodenal ulcer, and iron deficiency anemia.

In our study, dyspepsia was not the most common cause for contemplating *H. pylori* eradication. On the other hand, it should be mentioned that no evidence justifying the intentional search for *H. pylori* has been reported in patients with GERD, given that it has been demonstrated that there is no relation to symptoms, recurrence, and efficacy of treatment and its eradication does not exacerbate symptomatology (Level of evidence: 1a; Grade of recommendation: A). However, in our study, 82% of the participants considered that *H. pylori* was a cause of GERD symptoms.<sup>6</sup> This situation is peculiar and inappropriate and most certainly results in many patients unnecessarily receiving eradication treatment in Mexico.

Upon analyzing the symptoms that the general practitioners frequently related to *H. pylori* infection, it was obvious that they associated this bacterium with symptoms for which there is no causal relation, such as halitosis (50%) or abdominal bloating (48%). The fact that only 21% of the participants believed they had knowledge of the prevalence of this infection in Mexico should also be underlined. Even more alarming was how the range of the presumed knowledge went from *H. pylori* being considered a low prevalence infection (15%) to a very high prevalence infection (92%). Such epidemiologic knowledge is essential, given that many of the diagnostic and therapeutic decisions made should be based on the true prevalence of the disease.

Among the main noninvasive diagnostic studies are the urea breath test and the monoclonal antibody-based stool antigen test (Level of evidence: 2a; Grade of recommendation: B). However, our study showed that the most widely used noninvasive test was serology, likewise reported by Ahmed et al.,<sup>14</sup> Canbaz et al.,<sup>13</sup> and Ghanaei et al.,<sup>11</sup> reflecting the lack of adherence to the diagnostic recommendations. It is well known that serology is not useful for diagnosing active infection, much less for corroborating eradication, and its current usefulness is limited to epidemiologic studies. In fact, the most recent Maastricht V/Florence Consensus states that even though serologic tests can have high sensitivity and specificity, there can be positivity that is dependent on the antigen composition of the strains circulating in different geographic regions. In accordance with that consensus, serologic tests have limited clinical usefulness and their routine performance is not recommended.<sup>6</sup>

On the other hand, 31% of the physicians stated that they carried out more than one diagnostic test (usually 2) to diagnose *H. pylori* infection, and the most common combination was serology + histology. Albeit a minority, some physicians required 3 tests to make the diagnosis. Those results are striking, in that they reveal the lack of knowledge of the true clinical usefulness of the diagnostic tests or a lack of confidence as to their accuracy. Obviously, those practices result in great expense and are not very beneficial, significantly increasing costs in a country such as Mexico.

The therapeutic indications for *H. pylori* eradication are clearly specified in the Mexican Consensus on *Helicobacter*

*pylori*. Among the main indications are: gastric or duodenal peptic ulcer, atrophic gastritis and intestinal metaplasia, type B gastric lymphoma (MALT) of the marginal zone, a history of gastric cancer, and the chronic use of NSAIDs in patients with associated risk factors.<sup>7</sup> The same as in other studies involving primary care physicians, it was shown that the role of *H. pylori* eradication in patients with MALT gastric lymphoma was not known, and that eradication treatment was started without the support of an adequate diagnostic tool.

In Mexico, as in other parts of the world, first-line treatment continues to be the combination of a PPI plus amoxicillin and clarithromycin.<sup>15</sup> Even though 65% of the general practitioners used this regimen, it was surprising that the rest of the regimens were varied, or even included regimens with no recommendations or support. It was also striking that the second most widely used treatment was quadruple therapy that included metronidazole. As we know, resistance to that antibiotic is as high as 53%, which has limited its use in Mexico for many years.<sup>16,17</sup> And even though the percentage was very low, it was striking that regimens that have no scientific support were used, such as amoxicillin plus clavulanic acid or trimethoprim/sulfamethoxazole.

With respect to treatment duration, even though the majority of participants (75%) used eradication regimens for 14 days, 13% used regimens for more than 21 days and up to one month. Once again, not only is there a lack of evidence to support such prolonged schemes, but this type of recommendation can also be very costly, not well-tolerated (due to the side effects of the antibiotics), and promote the development of greater antimicrobial resistance.

The confirmation of eradication treatment is justified, for which there are noninvasive, easy-access methods, but the definitive choice of method depends on clinical context. Ahmed et al.<sup>13</sup> reported that the most frequently used method was the serology test (47%), followed by the urea breath test (35%). However, the primary care physicians surveyed considered endoscopy the first choice for carrying out histologic study (33%), ignoring the noninvasive techniques that imply less risk and lower cost. Endoscopy obviously involves high cost and its use in this context is not very practical, nor is there any scientific evidence to support it. In addition, the fact that close to 15% of the general physicians surveyed stated they required more than 3 tests to corroborate eradication, underlines their lack of confidence in the diagnostic tests.

Our study, despite its interesting results, had the limitation of being a survey that was cross-sectionally applied to a group of general physicians during an academic event, and thus the information obtained could have collection bias, selection bias, nonresponse bias, or the volunteer effect. In addition, the questionnaire was not validated for content, construct, criterion, or reliability. Even so, we believe that the data obtained realistically reflects the knowledge about *H. pylori* in our environment.

In conclusion, our results showed there is a lack of knowledge about the diagnostic and treatment recommendations established for *H. pylori* infection. Therefore, we consider this a point of special interest in relation to continuing medical education. The implementation of workshops, courses, and conferences, or the formulation of practical guidelines,

should be directed at primary care physicians to strengthen medical practice based on scientific evidence.

### **Ethical disclosures**

**Protection of human and animal subjects.** The authors declare that the procedures followed were in accordance with the regulations of the relevant clinical research ethics committee and with those of the Code of Ethics of the World Medical Association (Declaration of Helsinki).

**Confidentiality of data.** The authors declare that they have followed the protocols of their work center on the publication of patient data.

**Right to privacy and informed consent.** The authors have obtained the written informed consent of the patients or subjects mentioned in the article. The corresponding author is in possession of this document.

### **Conflict of interest**

Dr. José María Remes-Troche is a Member of the Advisory Board of Takeda Pharmaceuticals, Alfa-Wassermann, and Almirall. He is a Speaker for Takeda, Asofarma, Alfa-Wassermann, Almirall, and Astra-Zeneca.

**Annex 1. SURVEY The approach, attitudes, and knowledge about *Helicobacter pylori***

Instructions: This is an anonymous survey on what you know and perform in your daily clinical practice in relation to infection from the *Helicobacter pylori* bacterium.

Age \_\_\_\_\_ Sex \_\_\_\_\_ Speciality \_\_\_\_\_

1. Do you think that *Helicobacter pylori* infection conditions or produces GERD symptoms? 

YES	NO	DON'T KNOW
-----	----	------------
  
2. Do you think that *Helicobacter pylori* infection is the main cause of dyspeptic symptoms (epigastralgia, nausea, early satiety, gastric fullness)? 

YES	NO	DON'T KNOW
-----	----	------------
  
3. Which of the following symptom(s) do you think are associated with *Helicobacter pylori* infection? (you can mark more than one)
 

<input type="checkbox"/> Halitosis	<input type="checkbox"/> Excessive burping	<input type="checkbox"/> Dolor epigástrico
<input type="checkbox"/> Cough	<input type="checkbox"/> Heartburn	<input type="checkbox"/> Distención abdominal
<input type="checkbox"/> Pharyngitis	<input type="checkbox"/> Regurgitation	<input type="checkbox"/> Inflamación abdominal
<input type="checkbox"/> Asthma	<input type="checkbox"/> Chest pain	<input type="checkbox"/> Estreñimiento
<input type="checkbox"/> Dental erosion	<input type="checkbox"/> Early satiety	<input type="checkbox"/> Diarrhea
  
4. Do you know the percentage of *Helicobacter pylori* infection in the Mexican population: 

YES	NO
-----	----

 What is it? \_\_\_\_
  
5. 5. When do you consider giving *Helicobacter pylori* eradication treatment? (you can mark more than one)
 

<input type="checkbox"/> Never	<input type="checkbox"/> Patients with gastric cancer
<input type="checkbox"/> Always	<input type="checkbox"/> Patients with first degree relatives with gastric cancer
<input type="checkbox"/> Patients with reflux	<input type="checkbox"/> Patients with a history of ulcer
<input type="checkbox"/> Patients with dyspepsia	<input type="checkbox"/> Patients with chronic NSAID ingestion
<input type="checkbox"/> Patients with irritable bowel syndrome	
  
6. When you clinically suspect infection, how do you diagnose *Helicobacter pylori*? (Mark one or more of the following tests)
 

a) Serology      b) Histology      c) Breath test      d) Fecal antigen      e) All
  
7. When you prescribe eradication treatment, in which patients do you confirm *Helicobacter pylori* eradication?
 

a) All                      b) None                      c) In special cases
  
8. For how long do you indicate *Helicobacter pylori* eradication treatment?
 

a) 5 days    b) 7 days    c) 10 days    d) 14 days    e) 20 days    f) 30 days    g) Other \_\_\_\_\_
  
9. What is the *Helicobacter pylori* eradication treatment you most frequently use? (Describe it.)  
 \_\_\_\_\_  
 \_\_\_\_\_
  
10. How long after *Helicobacter pylori* eradication treatment do you order a diagnostic test to demonstrate eradication?  
 \_\_\_\_\_
  
11. When you wish to confirm eradication, which test do you use? (Mark one or more of the following)
 

a) Serology      b) Histology      c) Breath Test      d) Fecal antigen      e) All



## Referencias

1. Suerbaum S, Michetti P. *Helicobacter pylori* infection. *N Engl J Med*. 2002;347:1175–86.
2. Ishaq S, Nunn L. *Helicobacter pylori* and gastric cancer: A state of the art review. *Gastroenterol Hepatol Bed Bench*. 2015;8 Suppl 1:S6–14.
3. Bardhan PK. Epidemiological features of *Helicobacter pylori* infection in developing countries. *Clin Infect Dis*. 1997;25:973–8.
4. Hunt RH, Xiao SD, Megraud F, et al. Guías prácticas de la Organización Mundial de Gastroenterología: *Helicobacter pylori* en los países en desarrollo. *Gastroenterol Latinoam*. 2010;21:165–81.
5. Torres J, Leal-Herrera Y, Perez-Perez G, et al. A community-based seroepidemiologic study of *Helicobacter pylori* infection in Mexico. *J Infect Dis*. 1998;178:1089–94.
6. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of *Helicobacter pylori* infection—the Maastricht V/Florence Consensus Report. *Gut*. 2016;5, <http://dx.doi.org/10.1136/gutjnl-2016-312288>, pii: gutjnl-2016-312288.
7. Abdo-Francis JM, Uscanga L, Sobrino-Cossio S, et al. III Mexican consensus on *Helicobacter pylori*. *Rev Gastroenterol Mex*. 2007;72:323–38.
8. Huang J, Lam SK, Malfertheiner P, et al. Has education about *Helicobacter pylori* infection been effective? Worldwide survey of primary care physicians. *J Gastroenterol Hepatol*. 2003;18:512–20.
9. NIH Consensus Conference. *Helicobacter pylori* in peptic ulcer disease. NIH Consensus Development Panel on *Helicobacter pylori* in Peptic Ulcer Disease. *JAMA*. 1994;272:65–9.
10. Weijnen CF, Numans ME, de Wit NJ, et al. Testing for *Helicobacter pylori* in dyspeptic patients suspected of peptic ulcer disease in primary care: Cross sectional study. *BMJ*. 2001;323:71–5.
11. Ghanaei M, Joukar F, Soati F, et al. Knowledge and practice of general practitioners and internists about *Helicobacter pylori* infection in Guilan, Iran. *Middle East J Dig Dis*. 2011;3:119–25.
12. Montes Teves PA, Soria-Medina JI, Gamarra-Espinoza ZI, et al. The physician's attitude towards infection by *Helicobacter pylori* in clinical practice. *Rev Gastroenterol Peru*. 2002;22:221–7.
13. Canbaz S, Sunter AT, Peksen Y, et al. Survey of general practitioner's knowledge about *Helicobacter pylori* infection. *BMC Gastroenterology*. 2005;5:4.
14. Ahmed S, Salih M, Jafri W, et al. *Helicobacter pylori* infection: Approach of primary care physicians in a developing country. *BMC Gastroenterology*. 2009;9:23.
15. González-Huezo MS, Rojas-Sánchez A, Rosales-Solís AA, et al. *Helicobacter pylori* eradication frequency with the conventional triple therapy in adult patients at the Centro Médico Issemym. *Rev Gastroenterol Mex*. 2012;77:114–8.
16. Camargo MC, García A, Riquelme A, et al. The problem of *Helicobacter pylori* resistance to antibiotics: A systematic review in Latin America. *Am J Gastroenterol*. 2014;109:485–95.
17. Garza-González E, Pérez-Pérez GI, Alanís-Aguilar O, et al. Antibiotic susceptibility patterns of *Helicobacter pylori* strains isolated from northeastern Mexico. *J Chemother*. 2002;14:342–5.